Pfizer reported weight-loss results for a monthly GLP-1 obesity injection that it acquired as part of the $10 billion Metsera ...

A long-acting shot Pfizer got through a buyout of Metsera appeared “slightly inferior” to Lilly’s market-leading Zepbound in a Phase 2 trial, one analyst said.

Pfizer Inc. Buy: market overreacts to Q4 loss and 2026 guidance; oncology-led growth, 102-candidate pipeline, and dividend ...

Pfizer acquired the candidate following a bidding war with obesity giant Novo Nordisk for Metsera.

Good day, everyone, and welcome to Pfizer's Fourth Quarter 2025 Earnings Conference Call. Today's call is being recorded. At ...

To help answer common vaccine questions, we consulted Dr. Stanley Perlman, a professor at the University of Iowa’s Carver ...

Albert Bourla: 2025 was a very good year for Pfizer Inc. I'm very pleased with strong execution to deliver and, frankly, overdeliver on our financial commitments. If successful, we will substantially ...

Pfizer disclosed that an experimental weight loss drug, recently picked up through its acquisition of Metsera, hit its marks ...

Ultimately the committee must decide who is considered at high enough risk for an extra dose. Data provided by Pfizer and the ...

During a live event, Sumanta K. Pal and other oncologists discuss the safety and efficacy of belzutifan for advanced renal ...

The key alterations sought are FGFR3 activating mutations or fusions/rearrangements (“susceptible” alterations), for potential use of the FGFR inhibitor erdafitinib (Balversa), and HER2 IHC expression ...

Meanwhile, the U.K.'s Medicines and Healthcare Products Regulatory Agency updated its warnings on GLP-1 and dual GLP-1/GIP ...